XML 126 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
Restructuring Liability
3 Months Ended
Jun. 30, 2013
Restructuring and Related Activities [Abstract]  
Restructuring Liability
Restructuring Liability
In 2003, the Company adopted a plan to restructure its operations to coincide with its increasing internal emphasis on advancing drug candidates through clinical development to commercialization. The restructuring liability relates to specialized laboratory and office space that is leased to the Company pursuant to a 15-year lease that terminates in 2018, and that the Company has not used since it adopted the plan to restructure its operations in 2003. This laboratory and office space currently is subleased to third parties.
In estimating the expense and liability under its lease obligations, the Company estimated (i) the costs to be incurred to satisfy rental and build-out commitments under the lease (including operating costs), (ii) the lead-time necessary to sublease the space, (iii) the projected sublease rental rates and (iv) the anticipated durations of subleases. The Company uses a credit-adjusted risk-free rate of approximately 10% to discount the estimated cash flows. The Company reviews its estimates and assumptions on at least a quarterly basis, intends to continue such reviews until the termination of the applicable lease, and will make whatever modifications the Company believes necessary, based on the Company’s best judgment, to reflect any changed circumstances.
The activities related to the restructuring liability for the three and six months ended June 30, 2013 and 2012 were as follows:
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2013
 
2012
 
2013
 
2012
 
(in thousands)
Liability, beginning of the period
$
22,459

 
$
25,473

 
$
23,328

 
$
26,313

Cash payments
(3,849
)
 
(3,725
)
 
(7,422
)
 
(7,411
)
Cash received from subleases
2,666

 
2,488

 
5,331

 
4,974

Restructuring expense
776

 
594

 
815

 
954

Liability, end of the period
$
22,052

 
$
24,830

 
$
22,052

 
$
24,830